Lassa fever resources
PPE washing and drying station Lassa ward Owo
ISARIC is committed to strengthening the evidence base for Lassa fever therapeutics and improving case management. We have initiated a number of activities to address these knowledge gaps, which are conducted alongside a wide-range of partners and collaborators.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Visit this section to find ISARIC’s articles, studies and more.
Children older than 6 and with reported allergic diseases are at greater risk of Long COVID, paediatric study finds
Researchers from ISARIC (International Severe Acute Respiratory and emerging Infection Consortium) paediatric Long Covid working group in the UK, Sechenov University and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Russia ran the largest study to date on children hospitalised with COVID 19.
Ribavirin is the only available Lassa fever–specific treatment and has been used routinely for over 25 years. However, ribavirin is not licensed for Lassa fever, its mechanism of action is unclear, it is expensive and hard to source, and it has well-known toxicities.
Women under 50 and people who experienced severe disease had worse long-term outcomes following hospitalisation with COVID-19.